BLOG/🇮🇳India··daily

India Technology Sector Merger & Acquisition Filings — March 29, 2026

India Tech M&A Activity

7 medium priority7 total filings analysed

Executive Summary

Dominant M&A activity in India Tech/Packaging space centered on EPL Limited's scheme of amalgamation with Indovida India Private Limited across 5/7 filings, set to double standalone revenue from ₹4,568 Cr to proforma ₹8,377 Cr (CY25), boost EBITDA margin to 20.9%, EBIT margin +120 bps to 13.6%, and ROCE +220 bps to 20.9%, with $35-50M synergies from geographical diversification and efficiencies. CMS Info Systems' bolt-on acquisition of FSS ATM business adds ~8,000 units (expanding from 31,000 to 39,000) for ₹115 Cr, aligning with 11% CAGR guidance through FY30 on ₹1,300 Cr FY25 revenue base. Healthcare Global's SPA extension delays second closing by 3 weeks for Vizag Hospital stake. Portfolio-level trends show revenue scale-up averaging ~80% proforma for key deals, margin accretion, but public dilution in EPL from 74.03% to 31.63% amid promoter stake surge to 68.37%. Positive sentiment prevails (5/7 filings), signaling consolidation for emerging market growth, though approvals pending create timing risks. Critical implication: Enhanced scale positions merged entities for 20%+ ROCE outperformance vs. sector norms.

Tracking the trend? Catch up on the prior India Technology Sector Merger & Acquisition Filings digest from March 26, 2026.

Investment Signals(10)

  • Proforma revenue doubles to ₹83,767 Mn (CY25) from standalone ₹45,680 Mn, 20.9% EBITDA margin, net debt/EBITDA 0.25x low leverage

  • Merger EBIT margin accretive +120 bps to 13.6%, ROCE +220 bps to 20.9%, $35-50M synergies identified

  • Post-merger emerging markets revenue ~75%, global footprint expands to 211 sites across 111 countries vs. prior scale

  • ATM Managed Services acquisition adds 8,000 units (+25% to 39,000 total), ₹1,300 Cr FY25 revenue base with 11% CAGR to FY30

  • Deal aligns with consolidation strategy per Sept 2025 Analyst Day, strengthens pan-India 97% district coverage

  • Independent valuation and fairness opinion support arm's-length merger, share ratio 286:10,000 EPL:Indovida

  • Combined turnover ₹8,377 Cr (Indovida ₹3,809 Cr + EPL ₹4,568 Cr), net-worth boost from Indovida ₹6,459 Cr

  • Purchase consideration capped at ₹115 Cr for FSS ATM business (est. 1991), includes asset transfer and contract novation

  • Positive sentiment in 4/5 filings on synergies, diversification vs. mixed on dilution

  • SPA/SHA amendments enable 34% additional stake acquisition post-extension, maintaining deal momentum

Risk Flags(8)

  • Public shareholding dilutes sharply from 74.03% to 31.63%, promoter/promoter group rises to 68.37% fully diluted

  • Merger pending NCLT, SEBI, CCI, stock exchanges, shareholders, creditors approvals across all EPL filings

  • Post-merger IVL nominates 3+ directors (51.8% stake), Epsilon 1 (16.6%), reserved matters need dual approval

  • EPL shares valued at ₹339 reflecting 70% premium to March 27, 2026 close, potential overvaluation in swap

  • Second closing extended 3 weeks beyond original 18 months from Oct 2, 2024 first closing, signals delays

  • 1/5 EPL filings mixed sentiment citing dilution and board rights vs. positive on synergies

  • Q1 FY27 close for ₹115 Cr deal depends on asset transfer, customer contract novation

  • Low materiality (4/10) amendment with no other SPA/SHA changes, limited upside clarity

Opportunities(8)

Sector Themes(5)

  • M&A-Driven Scale Explosion

    6/7 filings show revenue boosts (EPL ~83% proforma, CMS +25% units), doubling EPL scale amid tech services consolidation [IMPLICATION: Outperformers emerge via inorganic growth]

  • Promoter Stake Consolidation

    EPL promoters to 68.37% (IVL 51.8%, Blackstone 16.6%), public dilution pattern signals control shift in packaging/tech M&A [IMPLICATION: Reduced free float, higher volatility]

  • Margin & ROCE Accretion

    EPL +120 bps EBIT to 13.6%, +220 bps ROCE to 20.9%; CMS 11% CAGR intact, vs. sector norms [IMPLICATION: Superior returns for acquirers post-synergies]

  • Pending Regulatory Hurdles

    All EPL/CMS/HCG deals cite approvals (NCLT/SEBI/CCI), extensions common (HCG +3 weeks) [IMPLICATION: Catalyst timing risks, binary outcomes]

  • Positive Sentiment Dominance

    5/7 positive/neutral, mixed only on EPL dilution; synergies/geography drive bullishness [IMPLICATION: M&A wave supports tech-adjacent rerating]

Watch List(7)

Filing Analyses(7)
EPL LimitedMerger/Acquisitionpositivemateriality 10/10

29-03-2026

EPL Limited's Board approved the scheme of amalgamation merging Indovida India Private Limited into the Company, increasing promoter/promoter group shareholding from 25.97% (84,479,781 shares) to 68.37% (348,701,552 shares) on a fully diluted basis, while diluting public stake from 74.03% to 31.63%. The merger, based on a share exchange ratio of 286 EPL equity shares (FV ₹2) for every 10,000 Indovida shares (FV ₹10) and supported by independent valuations and fairness opinion, aims to deliver synergies, geographical diversification, and operational efficiencies. As of Dec 31, 2025, EPL reported turnover of ₹4,568 Cr and net-worth of ₹1,717 Cr, while Indovida reported ₹3,809 Cr turnover and ₹6,459 Cr net-worth.

  • ·Share exchange ratio: 286 fully paid-up equity shares of EPL (FV ₹2 each) for every 10,000 fully paid-up equity shares of Indovida India (FV ₹10 each).
  • ·Merger subject to approvals from Stock Exchanges, SEBI, NCLT, CCI, shareholders, and creditors.
  • ·IVL to nominate at least 3 directors, Epsilon 1 director on EPL Board post-merger; certain reserved matters require prior approval of both.
  • ·Board meeting held on March 29, 2026 from 5:00 P.M. to 5:25 P.M. IST.
  • ·Valuation reports dated March 28, 2026 by independent valuers; fairness opinion by SEBI-registered merchant banker.
EPL LimitedMerger/Acquisitionpositivemateriality 10/10

29-03-2026

EPL Limited announces the Scheme of Amalgamation with Indovida India Private Limited, creating a merged entity with INR 83,767 million revenue (CY25 proforma), 20.9% EBITDA margin, and net debt/EBITDA of 0.25x, doubling scale from EPL's standalone INR 45,680 million. The merger is EBIT margin accretive (120+ bps to 13.6%) and ROCE accretive (220+ bps to 20.9%), with identified synergies of $35-50 million, though EPL's valuation at INR 339 per share reflects a 70% premium to the March 27, 2026 closing price. Approximately 75% of merged revenue from emerging markets supports growth potential amid stable profitability metrics.

  • ·Post-merger shareholding: Indorama Ventures 51.8%, Blackstone 16.6%, Public 31.6%
  • ·EPL global footprint: 211 manufacturing sites across 111 countries
  • ·Indovida 100% owned by Indorama Ventures Netherlands B V
  • ·Merged entity market positions leading in laminated tubes (EPL) and rigid PET (Indovida) across key emerging markets including Philippines, Vietnam, Nigeria, Egypt, Myanmar, Thailand, Tanzania, Ghana
  • ·Sustainability: EPL 90% recyclable tubes capacity, 21% renewable energy; Indovida 100% recyclable PET resin capacity, 150kMT rPET consumption goal by 2035
EPL LimitedMerger/Acquisitionmixedmateriality 9/10

29-03-2026

EPL Limited's Board approved the scheme of amalgamation merging Indovida India Private Limited into the Company, supported by a joint valuation and fairness opinion, aiming for synergies in packaging products, geographical diversification, and operational efficiencies with combined turnover of ₹8,377 Cr (Jan-Dec 2025). Post-merger, promoter/promoter group shareholding surges to 68.37% from 25.97% on a fully diluted basis, significantly diluting public holding to 31.63% from 74.03%. The merger, along with MIA, SHA, and TSA executions, remains subject to approvals from NCLT, CCI, SEBI, stock exchanges, and shareholders/creditors.

  • ·Share exchange ratio: 286 fully paid-up equity shares of EPL (FV ₹2 each) for every 10,000 fully paid-up equity shares of Indovida India (FV ₹10 each).
  • ·IVL to nominate at least 3 directors; Epsilon to nominate 1 director on EPL Board post-merger.
  • ·Company requires prior approval from Epsilon and IVL for certain reserved matters post-SHA.
  • ·Approvals required: Stock Exchanges, SEBI, NCLT, CCI, shareholders and creditors.
  • ·Board meeting: Mar 29, 2026, 5:00-5:25 PM IST.
  • ·Valuation reports and fairness opinion dated Mar 28, 2026.
Healthcare Global Enterprises LimitedMerger/Acquisitionneutralmateriality 4/10

29-03-2026

HealthCare Global Enterprises Limited executed second amendment agreements to the Share Purchase Agreement (SPA) and Shareholders Agreement (SHA) dated March 29, 2026, for the ongoing acquisition of Vizag Hospital and Cancer Research Centre Private Limited. The amendments extend the Second Closing Date by 3 weeks beyond the original 18 months from the First Closing Date of October 02, 2024, allowing the Company to acquire an additional 34% equity share capital. No other material changes were made to the SPA or SHA.

  • ·First Closing Date: October 02, 2024
  • ·Original Second Closing timeline: within 18 months of First Closing Date
  • ·Extension period: 3 weeks
  • ·Stock Codes: BSE – 539787, NSE – HCG
  • ·Disclosure reference: Regulation 30(2) and (6) read with Schedule III Part A Para A sub-para (1) of SEBI LODR Regulations, 2015 and SEBI Circular dated July 13, 2023
CMS Info Systems LimitedMerger/Acquisitionpositivemateriality 9/10

29-03-2026

CMS Info Systems Limited announced the acquisition of Financial Software and Systems Private Limited (FSS)'s ATM Managed Services business for a purchase consideration of up to ₹115 crores, adding ~8,000 units and expanding the managed services portfolio from ~31,000 to ~39,000 units. This transaction strengthens the ATM Management Solutions platform, which generated ~₹1,300 crores in FY25 services revenue with an 11% CAGR outlook through FY30, and is expected to close in Q1 FY27. The deal aligns with CMS's publicly stated consolidation strategy outlined at its September 2025 Analyst Day.

  • ·FSS established in 1991 with public and private sector banking clients
  • ·CMS's pan-India network spans 97% of districts
  • ·Transaction involves transfer of operating assets and novation of customer contracts
EPL LimitedMerger/Acquisitionpositivemateriality 9/10

29-03-2026

EPL Limited's Board approved the scheme of amalgamation merging Indovida India Private Limited into the Company on a going concern basis, with a share exchange ratio of 286 EPL equity shares (FV ₹2) for every 10,000 Indovida shares (FV ₹10), subject to approvals from NCLT, SEBI, CCI, stock exchanges, and shareholders/creditors. The merger is expected to deliver synergies including wider product range, cost savings, geographical diversification, and enhanced efficiencies in the packaging sector. Post-merger, promoter/promoter group shareholding will increase from 25.97% to 68.37% on a fully diluted basis.

  • ·IVL holds 99.99% of Indovida India and 24.44% in EPL; Epsilon holds 25.97% in EPL.
  • ·Merger at arm's length basis per independent valuers' report (Mar 28, 2026) and SEBI-registered merchant banker's fairness opinion.
  • ·Post-merger board rights: Epsilon nominates 1 director, IVL nominates at least 3; certain reserved matters require prior approval of both.
  • ·Approvals required: Stock Exchanges, SEBI, NCLT, CCI, requisite shareholders/creditors.
  • ·Board meeting: Mar 29, 2026, 5:00 P.M. to 5:25 P.M. IST.
EPL LimitedMerger/Acquisitionneutralmateriality 9/10

29-03-2026

EPL Limited's Board of Directors approved the Scheme of Amalgamation of Indovida India Private Limited (Transferor Company) with EPL Limited (Transferee Company) on March 29, 2026. The company has scheduled an investors' and analysts' conference call on March 30, 2026, at 11:00 AM IST to discuss the scheme, with participation from MD & Global CEO Hemant Bakshi, COO M.R. Ramasamy, CFO Deepak Goyal, and Head Legal Onkar Ghangurde. No financial details or performance metrics were disclosed in this intimation.

  • ·ISIN: INE255A01020
  • ·Scrip Code: 500135
  • ·Trading Symbol: EPL
  • ·Conference call dial-in: Primary +91 22 6280 1297, Secondary +91 22 7115 8198
  • ·Toll-free numbers: USA 1 866 746 2133, UK 0 808 101 1573, Singapore 800 101 2045, Hong Kong 800 964 448
  • ·Diamond Pass: https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=4568962&linkSecurityString=2527b7a15e

Get daily alerts with 10 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 7 filings

🇮🇳 More from India

View all →
India Technology Sector Merger & Acquisition Filings — March 29, 2026 | Gunpowder Blog